Literature DB >> 10418057

Young age at onset, renal involvement, and arterial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematosus.

R Marini1, L T Costallat.   

Abstract

OBJECTIVE: To look for associations between mortality, clinical or laboratory data, and age at disease onset in systemic lupus erythematosus patients aged 16 years or younger at disease onset. PATIENTS AND METHODS: The medical records of patients seen at the Clinics Hospital, State University of Campinas, São Paulo, Brazil, between 1979 and 1995 were reviewed retrospectively. All 59 included patients (48F/11M) fulfilled four or more American College of Rheumatology criteria for systemic lupus erythematosus. Patients with discold, drug-induced or neonatal lupus, or other systemic connective tissue diseases were excluded. Patients were studied individually then classified in three groups based on age at disease onset, as follows: Group I, < or = 9 years of age; Group II, 10-14 years of age; and Group III, 15-16 years of age. Clinical and laboratory abnormalities and mortality were compared in the three groups.
RESULTS: The most frequent clinical manifestations were joint symptoms (91.5%), renal involvement (71.1%), malar rash (61%), alopecia (61%), fever (59.3%) and photosensitivity (52.5%). Laboratory findings included antinuclear antibody in 94.9% of cases. LE cells in 71.1%, low serum complement in 65.3%, anti-DNA in 63.4%, hematuria in 62.7%, and proteinuria in 61%. The mortality rate was 23.7% (9F/5M) overall, 18.7% in females, and 45.4% in males (P = 0.07). The cause of death was infection in eight patients (57.1% of decedents), central nervous system disease in five (35.7%), and renal insufficiency in one (7.2%). Disease onset before 15 years of age (P = 0.026), renal involvement (P = 0.03), and arterial hypertension (P = 0.002) were predictive of mortality. Mortality was not influenced by gender or race.

Entities:  

Mesh:

Year:  1999        PMID: 10418057

Source DB:  PubMed          Journal:  Rev Rhum Engl Ed        ISSN: 1169-8446


  13 in total

1.  Antinuclear antibody (ANA) profile testing of ANA- positive patients.

Authors:  G S Hauksdóttir; T Jónsson; O J Mellbye
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

2.  Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis.

Authors:  Stephen D Marks; Vanita Shah; Clarissa Pilkington; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2010-08-05       Impact factor: 3.714

3.  Clinicopathological correlations of paediatric lupus nephritis.

Authors:  Stephen D Marks; Neil J Sebire; Clarissa Pilkington; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2006-11-15       Impact factor: 3.714

4.  Damage did not independently influence mortality in childhood systemic lupus erythematosus.

Authors:  Simone Appenzeller; Roberto Marini; Lilian T L Costallat
Journal:  Rheumatol Int       Date:  2005-02-10       Impact factor: 2.631

Review 5.  Use of biomarkers in the management of children with lupus.

Authors:  Elisabeth Binder; Monika Edelbauer
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

6.  Systemic lupus erythaematosus in a multiethnic US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus.

Authors:  A M Bertoli; L M Vilá; J D Reveille; G S Alarcón
Journal:  Ann Rheum Dis       Date:  2007-08-24       Impact factor: 19.103

7.  Reduced albumin levels and utilization of arteriovenous access in pediatric patients with systemic lupus erythematosus (SLE).

Authors:  Sangeeta D Sule; Jeffrey J Fadrowski; Barbara A Fivush; Gregory Gorman; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2007-09-28       Impact factor: 3.714

Review 8.  Urine biomarkers in juvenile-onset SLE nephritis.

Authors:  Louise Watson; Michael W Beresford
Journal:  Pediatr Nephrol       Date:  2012-05-16       Impact factor: 3.714

9.  Persistent low albumin and temporary vascular access in pediatric patients with SLE on hemodialysis.

Authors:  Sangeeta D Sule; Jeffrey J Fadrowski; Barbara A Fivush; Alicia M Neu; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2009-06-13       Impact factor: 3.714

Review 10.  Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.

Authors:  Stephen D Marks; Kjell Tullus
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.